Adjuvant Fuzheng Huayu Capsule Reduces the Incidence of Hepatocellular Carcinoma in Patients with Hepatitis B-Caused Cirrhosis

Table 3

Risk of hepatocellular carcinoma according to the cumulative use of FZHY among patients with hepatitis B-caused cirrhosis.

No. of FZHY days	Total	HCC	Hazard ratio (95% CI)
	(n = 518)	(n = 86)	Crude^†		Adjust
Control group	259	60	Reference		Reference
FZHY group	259	26	0.39 (0.25–0.62)		0.32 (0.19–0.53)
<12 months	82	15	0.77 (0.44–1.37)		0.66 (0.35–1.24)
12–36 months	131	11	0.32 (0.18–0.62)		0.28 (0.15–0.54)
>36 months	46	0	0.04 (0.01–0.70)		0.04 (0.01–0.70)

Data are presented as hazard ratios (95% confidence intervals). . Crude HR represents relative hazard ratio. . Adjusted HR represents multivariate-adjusted hazard ratio: age, sex, drinking, total bilirubin, albumin, white blood cell count, platelets, creatinine, blood urea nitrogen, international normalized ratio, prothrombin activity, alpha-fetoprotein, and HBV DNA. FZHY: Fuzheng Huayu capsule.